Synlogic
OTC: SYBXCambridge, US · Founded 2014 · Delaware corporation · 7 known investors
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.
BiotechDeep TechMedical Devices
Founders & leadership
BC
Bharatt ChowriraExecutive
MS
Michael SheahanExecutive
JC
Jose Carlos Gutierrez-RamosExecutive
PM
Paul MillerExecutive
AB
Aoife BrennanExecutive
TS
Todd ShegogExecutive
DG
DANIEL GEFFKENNamed on SEC filing
EM
ED MATHERSNamed on SEC filing
PB
PETER BARRETTNamed on SEC filing
AM
ANKIT MAHADEVIANamed on SEC filing
LG
LEWIS GEFFENNamed on SEC filing
Board
EM
Investors · 7
Atlas VentureCambridge · $500K – $1M
NSG VenturesSingapore
Pfizer Venture Investments$5M – $20M
Sofinnova VenturesMenlo Park · $100K – $15M
Solasta VenturesBoston
New Enterprise Associates (NEA)reportedMenlo Park · $200K – $40Mvia Ed Mathers · board
OrbiMedreportedNew York · $1M – $75Mvia Chau Khuong · board
Reported raises · per SEC filings
Form D private placements$77M disclosed across 4 rounds · 2014–2017
▶$42MraisedMay 2017 · 16 investors · BiotechnologyRule 506(b)
▶$42MraisedMay 2017 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul MillerExecutive Officer
- Peter BarrettDirector
- Chau KhuongDirector
- Aoife BrennanExecutive Officer
- Nick LeschlyDirector
- Lewis GeffenExecutive Officer
- Jose Carlos Gutierrez-RamosExecutive Officer, Director
- Ed MathersDirector
- Todd ShegogExecutive Officer
- Offering amount
- $42M
- Amount sold
- $42M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$17.1MraisedFeb 2016 · 3 investors · BiotechnologyRule 506(b)
▶$17.1MraisedFeb 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ed MathersDirector
- Chau KhuongDirector
- Bharatt ChowriraExecutive Officer
- Ankit MahadeviaDirector
- Michael SheahanExecutive Officer
- Peter BarrettDirector
- Jose Carlos Gutierrez-RamosExecutive Officer, Director
- Lewis GeffenExecutive Officer
- Offering amount
- $17.1M
- Amount sold
- $17.1M
- First sale
- Feb 2016
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$13.9MraisedFeb 2016 · 2 investors · BiotechnologyRule 506(b)
▶$13.9MraisedFeb 2016 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jose Carlos Gutierrez-RamosExecutive Officer, Director
- Ed MathersDirector
- Lewis GeffenExecutive Officer
- Bharatt ChowriraExecutive Officer
- Michael SheahanExecutive Officer
- Peter BarrettDirector
- Chau KhuongDirector
- Ankit MahadeviaDirector
- Offering amount
- $40.6M
- Amount sold
- $13.9M
- First sale
- Feb 2016
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$4MraisedJul 2014 · 2 investors · BiotechnologyRule 506(b)
▶$4MraisedJul 2014 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DANIEL GEFFKENExecutive Officer
- ED MATHERSDirector
- PETER BARRETTDirector
- ANKIT MAHADEVIAExecutive Officer, Director
- LEWIS GEFFENExecutive Officer
- Offering amount
- $29.4M
- Amount sold
- $4M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapAbiologics30 shared keywordsAbiologics uses generative AI and high-throughput chemical protein synthesis to design and produce Synteins, a new class of programmable, protease-resistant, immune-silent biologic therapeutics. The company targets a range of disease areas, including oncology, immunology, and metabolic diseases.
Bioworld21 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Sentynl21 shared keywordsSentynl Therapeutics is a pharmaceutical company that develops and commercializes prescription therapies, including ZYCUBO (copper histidinate), which has received FDA approval. It provides access, support, and medical affairs services for its products.
Senti Biosciences19 shared keywordsSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.
Syneos Health18 shared keywordsSyneos Health is a contract research and commercialization services company that supports biopharmaceutical companies in drug development, regulatory affairs, and market launch across therapeutic areas. The firm employs over 26,000 specialists including MDs and PhDs to help clients develop and commercialize pharmaceuticals globally.
Companies competing with Synlogic for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Synlogic do?
- Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.
- Who are Synlogic's investors?
- Synlogic's investors include Atlas Venture, NSG Ventures, Pfizer Venture Investments, Sofinnova Ventures, Solasta Ventures, New Enterprise Associates (NEA), OrbiMed.
- How much funding has Synlogic raised?
- Synlogic has disclosed $77M raised across 4 rounds.
- Where is Synlogic headquartered?
- Synlogic is headquartered in Cambridge, US.